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Abstract: The effect of obesity on ovarian response to ovulation induction and on in vitro fertilization (IVF) outcome is 
controversial. This controversy might stem from the fact that almost all studies on the subject use body mass index (BMI) 
for obesity measurement. We aimed to determine which obesity measure predicts the possible effect of obesity on 
ovarian response in IVF patients. In this retrospective study, patients who presented for IVF and underwent an 
antagonist protocol were included. Their histories and cycle properties were recorded, as well as their BMI and waist-to-
hip (W/H) ratios. A total of 35 patients were included. While normal BMI significantly lowered the gonadotropin dose, 
normal W/H ratio increased the antral follicle count (AFC). Both BMI and W/H ratio did not significantly affect either the 
number of oocytes retrieved or the metaphase II oocytes. Ovulation induction during IVF cycles can overcome the 
adverse effects of obesity on ovarian reserve. Large-sample-sized, well-designed studies must be performed to clarify 
the best obesity measurement method for infertility treatment and to determine the real effect of obesity on IVF success. 
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INTRODUCTION 
Obesity is a serious current health problem and its 
relationship with many diseases is well-established. 
Many studies have been conducted on the effect of 
obesity on in vitro fertilization (IVF) success and 
ovarian response.  
Bellver et al. [1] showed that obesity interferes with 
embryo quality and cleavage patterns in IVF cycles. A 
study published in 2012 showed that obesity did not 
have an adverse effect on embryo quality or pregnancy 
outcome in women under 38 years of age [2]. Haqhighi 
et al. [3] demonstrated that obesity did not have any 
effect on IVF success. Only morbid obesity was shown 
to have an effect on clinical pregnancy outcomes, and 
IVF success in obese and overweight women was 
comparable to that of normal weight women [2]. While 
some studies failed to show a relationship between 
obesity and IVF outcome [4], other studies could only 
determine a relationship between obesity and 
retrieved-oocyte numbers in diminished ovarian 
reserve patients [5]. 
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On the other hand, a review from Turkey 
emphasized that obesity interferes with many steps of 
IVF treatment, including oocyte retrieval [6]. Moragianni 
et al. [7] demonstrated adverse effects of obesity on 
IVF outcomes in their large-sample-sized retrospective 
study. In a meta-analysis [8] and in a multi-center study 
[9], the authors concluded that obesity had unfavorable 
effects on IVF outcome. Shah et al. [10] showed that 
although obesity did not affect the number of retrieved 
oocytes, it had some adverse effects on oocyte quality 
and fertilization.  
Literature on the subject has had controversial 
outcomes. Almost all studies conducted on this subject 
used body mass index (BMI) as the measure of 
obesity; however, using only BMI might be the wrong 
strategy. Interestingly, some studies on the 
cardiovascular system found protective effects of BMI 
and as a result a new term, ‘obesity paradox,’ 
emerged. Later studies used waist-to-hip (W/H) ratio 
and wrist circumference (WC) as a measure of obesity, 
and showed the exact effect of body fat distribution and 
obesity on the cardiovascular system [11]. 
We aimed to determine which obesity measure 
predicts the possible adverse effects of obesity on the 
number of oocytes retrieved and the cycle outcomes in 
intracytoplasmic sperm inoculation (ICSI) patients on 
an antagonist cycle. 
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MATERIALSAND METHODS 
This retrospective study was conducted at the IVF 
clinic of Gulhane Military Medical Academy. Ethical 
committee consent was obtained for the study. Patients 
who presented to the clinic between April 1 and 
December 31, 2013, and who underwent an antagonist 
protocol were included. 
Patients with ovarian cysts or endometriomas, who 
had a history of operations that might affect ovarian 
reserve, who had polycystic ovarian syndrome (PCOS) 
according to the Rotterdam criteria, who were older 
than 40 years of age, and who had chronic disease 
were excluded.  
Sociodemographic properties and histories, 
including the cycle properties of the participants, were 
recorded. Early follicular-phase antral follicle count 
(AFC), 8-hour fasting weight, height, and waist and hip 
circumferences were measured, and W/H and BMI 
were calculated as defined in our previous study 
[12].Overweight was defined as BMI 25 kg/m2 and 
obese was defined as BMI 30 kg/m2[13].W/H ratio 
0.85 was defined as normal and >0.85 was defined as 
high. 
A fixed antagonist protocol was started on all 
patients. Gonadotropin was started on the third day of 
the menstrual cycle. The starting dose was determined 
according to the individual’s age, BMI, and AFC. 
According to the ovarian response of the patient, 
gonadotropin doses were adjusted. On day 5, the 
antagonist was started in each patient with 0.25 mg of 
subcutaneous cetrorelix daily until the ovulation trigger 
day. When at least 2 follicles were >18 mm, ovulation 
trigger was done with 250 mcgof chorionic 
gonadotropin alpha. Thirty-six to 38 hours after 
ovulation trigger, oocyte pick-up (OPU) was performed 
under general anesthesia. All oocytes were counted 
and graded by an embryologist, and MI and MII 
oocytes underwent the ICSI procedure. Total 
gonadotropin dose used, duration of ovulation 
induction, and the number and grades of oocytes were 
recorded.  
Statistical analysis was performed with the 
Statistical Package for Social Sciences version 15.0 
(SPSS Inc., Chicago, IL). All continuous variables were 
expressed as mean ± standard deviation (SD). All 
measurements were evaluated with the Kolmogorov–
Smirnov test and the Shapiro-Wilk test to determine 
normal distribution. A p-value <0.05 was accepted as a 
significant result. 
RESULTS 
A total of 35 patient who met the inclusion criteria 
were included. Their mean age was 31.48±3.71 years, 
infertility duration was 4.8±3.51 years, FSH level was 
6.73±2.82 IU/L, and BMI was 25.65 kg/m
2
. 
Participants were divided into two groups according 
to BMI. There were 23 normal-weight and 12 
overweight/obese patients. Sociodemographic and 
cycle properties of the participants according to their 
BMI are described in Table 1.  
Participants were also divided into two groups 
according to their W/H ratio. There were 21 patients in 
the normal group and 14 patients in the high W/H ratio 
group. Sociodemographic and cycle properties of the 
groups are described in Table 2. 
Normal BMI resulted in significantly lower 
gonadotropin doses and normal W/H ratio resulted in 
significantly high AFCs. Neither BMI nor W/H ratio 
significantly affected oocyte numbers. 
DISCUSSION AND CONCLUSION 
In the current study, we showed that ovulation 
induction for the IVF cycle can overcome the effects of 
Table 1: Socio-Demographic and Cycle Properties of Participants According to BMI 
 Normal (BMI25kg/m2) Obese (BMI<25kg/m2) P 
Age 
FSH (IU/L) 
E2 (pg/ml) 
LH (IU/L) 
AFC 
Gonadotropin dose 
Ovulation induction duration (day) 
Number of oocytes 
Number of MII oocytes 
31.21 
6.99 
64.10 
6.09 
10.68 
1912.50 
8.83 
9.22 
7.13 
32.00 
6.23 
43.40 
4.95 
7.64 
2541.67 
9.50 
8.42 
5.83 
0.562 
0.460 
0.205 
0.380 
0.066 
0.047 
0.281 
0.648 
0.451 
Obesity and Oocyte Number in IVF Cycles International Journal of Gynecology, Obstetrics and Neonatal Care, 2015, Vol. 2, No. 1    21 
obesity on ovarian reserves. Although a high W/H ratio 
caused lower AFC, the numbers of oocytes retrieved in 
normal and high W/H ratio groups were not significantly 
different. While high W/H ratio caused lower AFC, 
higher BMI did not cause significant changes in AFC. 
The W/H ratio is a better obesity marker than BMI in 
predicting AFC. Higher BMI causes higher 
gonadotropin dose requirements for ovulation induction 
in IVF cycles. 
In a review, not only being obese but also being 
overweight was shown to be a risk factor for increased 
gonadotropin doses and decreased pregnancy rates in 
IVF cycles [14]. In a study that evaluated 220 IVF 
cycles, patients with W/H0.80 had a significantly 
decreased pregnancy rate [15], but the authors did not 
mention the number of oocytes retrieved. Moreover, 
they included PCOS patients in the study. In a large-
sample-sized retrospective study, obesity was found to 
be related to cycle cancellation and ovarian response, 
but did not interfere with pregnancy rates [16]. Van 
Swieten [17] also reached similar conclusions. Zhang 
et al. [18] showed that increased BMI resulted in 
increased gonadotropin doses and induction length, 
and decreased numbers of retrieved oocytes,but they 
did not find any effect on pregnancy outcome. Depalo 
[19] found that obesity resulted in both increased 
gonadotropin doses and IVF success. 
In contrast, some studies failed to show a 
relationship between obesity and IVF success. 
Although obesity caused increased gonadotropin 
doses, intrauterine insemination [20], IVF [21, 22], and 
ICSI [23] success was not decreased. No relationship 
was established between BMI and anti-Müllerian 
hormone [24] or between BMI and AFC [25].  
Vilarino et al. [26] concluded that BMI was not a 
good predictor of IVF success, and other 
measurements for obesity must be studied for this 
purpose. 
Marci et al. [22] evaluated 463 patients, and BMI25 
resulted in increased gonadotropin dose but did not 
change cycle length or the number of retrieved 
oocytes. Haghigi et al. [3] reviewed 230 first IVF cycles 
and could not find any relationship between BMI and 
gonadotropin dose, retrieved oocyte numbers, and 
mature oocyte numbers. Among PCOS patients, obese 
and overweight women had significantly decreased 
numbers of retrieved oocytes and fewer good-quality 
embryos and implantations [27]. Also, higher 
gonadotropin doses and increased cycle lengths were 
required.  
The strength of the current study was the exclusion 
criteria that interfere with ovarian response and the 
homogeneity of the protocol used for ovulation 
induction. With those strict selection criteria, many 
confounding factors were eliminated. The major 
limitation was the small sample size of the study. 
To our knowledge, this is the first study that 
searches for the best predictive obesity measurement 
to estimate ovarian response to ovulation induction for 
IVF. 
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